Company profile
UK company 06517359, incorporated on 28 February 2008.
CN Bio | Predictive Organ-on-a-chip Drug Discovery Models
CN Bio is a world leading organ-on-a-chip company. We empower you to transform drug discovery with our predictive human organ models.
Company number 06517359
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jan 2021 to 30 Jun 2022
The SARS-CoV-2 (COVID-19) pandemic has been met with an unprecedented global response from the scientific and medical communities, to accelerate understanding and ultimately treatment and prophylaxis of the virus. An overwhelming need for new or re-purposed medicines and tools for their discovery exists. Currently, discovering and developing new medicines...
1 Oct 2017 to 31 Mar 2019
Only 1 in 10 of all new drugs makes it through clinical trails to become an approved medicine, which is a signifciant problem for the pharmaceutical industry. However if these failures are due to a lack of efficacy, then it may be possible to repurpose drugs in a new disease areas. Non-alcoholic fatty liver disease (NAFLD) presents a significant unmet med...
1 Feb 2017 to 31 Dec 2017
Development of credible non-animal technologies is necessary before well-established animal tests can be eliminated from drug discovery, chemicals testing and basic research. Miniature devices that replicate human organ function in the laboratory, so-called "Organs-on-Chips", have already been used in the race to discover new medicines to treat viral infe...
1 Jan 2016 to 31 Dec 2017
NASH presents a significant unmet medical need in more economically developed nations, affecting up to 5% of the US population alone. There is currently no medical treatment for NASH, where the condition is a precursor to cirrhosis and hepatocellular carcinoma, conditions with very poor prognoses. One key limiting factor in the development of a treatment ...
1 Sep 2014 to 30 Nov 2015
Non-alcoholic fatty liver disease (NAFLD) encompasses a range of conditions from fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH). NAFLD is a condition affecting around 30 % of the general population and 70 % of obese and diabetic patients. The prevalence of NAFLD is set to rise as the obesity and diabetic pandemic escalates. It is therefor...
1 Aug 2010 to 31 Mar 2011
Awaiting Public Summary
